Table 2.
Socio-demographic and clinical characteristics of HOMER cohort participants up to administrative censoring on 30 June 2012, the study end-date for the HOMER cohort at the time of writing (n = 5229)
| Variable | Number (%) or median (quartiles 1–3) |
|---|---|
| Sex | |
| Female | 985 (18.8) |
| Male | 4244 (81.2) |
| Resident in an urban localitya | 4090 (95.2) |
| Current age (years) | 48 (41–55) |
| Age at enrolment (years) | 41 (34–47) |
| Baseline CD4 cell count (cells/mm3) | 210 (110–330) |
| Most recent CD4 cell count (cells/mm3) | 450 (270–640) |
| Baseline plasma viral load (copies/ml) | 95 000 (30 700–100 010) |
| Recent viral suppression (≤50 copies/ml)b | 3673 (74.6) |
| Viral load test rate (per year follow-up) | 4.2 (3.1–5.2) |
| AIDS at baseline | 781 (14.9) |
| HIV risk factorc | |
| History of injection drug use | 2031 (38.8) |
| Heterosexual | 1207 (23.1) |
| MSM | 1310 (25.1) |
| Unknown | 1741 (33.0) |
| Hepatitis C-positive | 2193 (41.9) |
| Ethnicityc | |
| White | 1836 (35.1) |
| Aboriginal ancestry | 684 (13.1) |
| Asian | 190 (3.6) |
| Hispanic | 112 (2.1) |
| Black | 117 (2.2) |
| Unknown | 2449 (46.8) |
| Loss to follow-upd | 238 (4.6) |
| Total follow-up time (years) | 5 (3–9) |
| Crude mortality | 993 (19.0) |
| Years on ART | 4 (2–7) |
| Baseline ART resistance testing | 2839 (54.3) |
| Resistance mutations detected | 234 (8.24) |
| Treatment interruption (≥90 days) in past year of follow-up | 627 (13.0) |
| Adherence ≥95% in past year of follow-upe | 2903 (60.0) |
This table displays socio-demographic and clinical characteristics of all HOMER cohort participants up to administrative censoring, including participants who have died, moved out of BC or become lost to follow-up.
MSM, men who have sex with men; ART, antiretroviral therapy.
aDetermined by postal code data (data missing for 933 individuals).
bPlasma viral load within 12 months before last follow-up date. Viral load assays taken after April 1999 exclusively included, to reflect guideline changes and sensitivity of testing (data excluded for 305 individuals).
cIn some cases participants may identify with more than one HIV risk factor/ethnicity, therefore the total percentage is greater than 100.
dDefined as no clinical contact for ≥18 months.
eDetermined by pharmacy refill data. Individuals eligible for adherence assessment must have ≥12 months of follow-up (n = 4842).